EcoDrugPlus

Toll Like Receptor 7

Ensembl ID : ENSLLEG00000003647
Gene Symbol: TLR7
1 View Cross-references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Trace Amine Associated Receptor 1

Ensembl ID : ENSLLEG00000014417
Gene Symbol: TAAR1
1 View Cross-references
602 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSLLEG00000007741
Gene Symbol: TRPA1
1 View Cross-references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSLLEG00000017415
Gene Symbol: TRPM8
1 View Cross-references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSLLEG00000002955
Gene Symbol: TRPV1
1 View Cross-references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Translocator Protein

Ensembl ID : ENSLLEG00000010665
Gene Symbol: TSPO
1 View Cross-references
126 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transthyretin

Ensembl ID : ENSLLEG00000018407
Gene Symbol: TTR
1 View Cross-references
178 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tryptophan Hydroxylase 1

Ensembl ID : ENSLLEG00000009964
Gene Symbol: TPH1
1 View Cross-references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 4a

Ensembl ID : ENSLLEG00000026353
Gene Symbol: TUBA4A
1 View Cross-references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 2a Class Iia

Ensembl ID : ENSLLEG00000007597
Gene Symbol: TUBB2A
1 View Cross-references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta Class I

Ensembl ID : ENSLLEG00000025545
Gene Symbol: TUBB
1 View Cross-references
355 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tyrosinase

Ensembl ID : ENSLLEG00000023613
Gene Symbol: TYR
1 View Cross-references
266 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).